EYPT EyePoint Pharmaceuticals Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 27 January 2020 EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize DEXYCU® for Post-operative Inflammation in Mainland China, Hong Kong, Macau and Taiwan

   WATERTOWN, Mass., Jan. 27, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Ocumension

2. 23 January 2020 EyePoint Pharmaceuticals Announces Preliminary Fourth Quarter and Full-Year 2019 Revenues

   - Q4 2019 total revenues are estimated to be between $7.5 - $8.2 million and full-year 2019 total revenues are estimated to be between $19.3 - $20.0 million - - Q4 2019 net product revenues are estimated to be between

3. 04 December 2019 EyePoint Pharmaceuticals Announces New Agreement for Expanded Access of DEXYCU® Within One of the Largest Integrated Delivery Systems in the U.S.

   WATERTOWN, Mass., Dec. 04, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today

4. 19 November 2019 EyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility

   WATERTOWN, Mass., Nov. 19, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today

5. 14 November 2019 EyePoint Pharmaceuticals Appoints George O. Elston as Chief Financial Officer and Head of Corporate Development

   WATERTOWN, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today

6. 07 November 2019 EyePoint Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate Progress

   – U.S. commercial launch trajectory for DEXYCU® and YUTIQ® gains momentum with strong customer order growth over Q2 – – DEXYCU customer orders increased 207% over Q2 with repeat customers representing 74% of order

7. 04 November 2019 EyePoint Pharmaceuticals Announces Addition of DEXYCU® and YUTIQ® to Department of Veteran Affairs Federal Supply Schedule

   - DEXYCU and YUTIQ now available across the VA and on Federal Supply Schedule to benefit U.S. veterans and other government employees - WATERTOWN, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals,

8. 01 November 2019 EyePoint Pharmaceuticals Secures New Patient Access Agreement with Vizient Inc. for DEXYCU®

   WATERTOWN, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today

9. 24 October 2019 EyePoint Pharmaceuticals Announces Third Quarter 2019 Financial Results Release Date and Conference Call Information

   WATERTOWN, Mass., Oct. 24, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will

10. 02 October 2019 EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for YUTIQ® Now in Effect

    WATERTOWN, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products,

11. 27 September 2019 EyePoint Pharmaceuticals Announces YUTIQ® Presentations at the American Academy of Ophthalmology 2019 Annual Meeting

    WATERTOWN, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today

12. 26 September 2019 EyePoint Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

    WATERTOWN, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today

13. 09 September 2019 EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 52nd Annual Retina Society Scientific Meeting

    WATERTOWN, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today